Memorial Sloan Kettering Cancer Center is home to more than 20,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer.

With an exceptional record of innovation, our research community has produced technologies that have thus far yielded 11 drugs that have been approved by the US Food and Drug Administration — with others in promising stages of clinical development. While these drugs themselves are not “digital,” the MSK infrastructure, technologies, and data that have helped develop them hold great potential for the digital health field.

At MSK, we are leaders in the field of digital health. Our investigators, clinicians, and health technology professionals are working on a wide range of opportunities to bring the promise of our cutting-edge technologies, deep expertise in clinical validation, and portfolio of digital assets to our mission of improving the health care and quality of life of people with cancer. Illustrative projects span early detection and screening, biomarker and algorithmic predictors, clinical trials and treatment, imaging and genomic testing, monitoring and recurrence, patient-reported outcomes, curated data-driven insights, and digital solutions for remote care and data curation.

Paige.AI, a global leader in digital diagnostics, was founded in 2017 as an MSK startup company and it offers a good example of MSK impact and innovation in the field of digital health. In September 2021, it received the first-ever FDA approval for an A.I. product in digital pathology.

MSK’s Digital Health initiative includes exceptional licensing opportunities for industry, including OncoKB®, a pathbreaking precision oncology knowledge base of over 5,000 gene alterations powered by the clinical expertise of MSK. Other opportunities include an ever-expanding array of MSK oncology applications, algorithms, and extensive de-identified clinicogenomic data assets that can be curated and provide valuable insights for research purposes across multiple oncology sub-specialties.

We offer options for strategic collaboration, including the MSK Innovation Hub, a program that provides corporate innovators in the field of digital health with access to scientific innovators at MSK and other unique institutional assets.

The Office of Technology Development’s Digital Health Team manages MSK’s digital asset pipeline and is the point of contact for industry.

Explore some of our opportunities below. Some of our newest digital health licensing opportunities may not appear on this list. To learn about recent developments, contact Rick Peng, Innovation Hub Manager and Digital Licensing Professional in the Office of Technology Development, at [email protected].